Vaccines Against Human Diarrheal Pathogens: Current Status and Perspectives

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2014 May 28

PMID 24861668

Citations 8

Authors

Nathalie Bohles

Kim Busch

Michael Hensel

Affiliations

Soon will be listed here.

Abstract

Worldwide, nearly 1.7 billion people per year contract diarrheal infectious diseases (DID) and almost 760 000 of infections are fatal. DID are a major problem in developing countries where poor sanitation prevails and food and water may become contaminated by fecal shedding. Diarrhea is caused by pathogens such as bacteria, protozoans and viruses. Important diarrheal pathogens are Vibrio cholerae, Shigella spp. and rotavirus, which can be prevented with vaccines for several years. The focus of this review is on currently available vaccines against these three pathogens, and on development of new vaccines. Currently, various types of vaccines based on traditional (killed, live attenuated, toxoid or conjugate vaccines) and reverse vaccinology (DNA/mRNA, vector, recombinant subunit, plant vaccines) are in development or already available. Development of new vaccines demands high levels of knowledge, experience, budget, and time, yet promising new vaccines often fail in preclinical and clinical studies. Efficacy of vaccination also depends on the route of delivery, and mucosal immunization in particular is of special interest for preventing DID. Furthermore, adjuvants, delivery systems and other vaccine components are essential for an adequate immune response. These aspects will be discussed in relation to the improvement of existing and development of new vaccines against DID.

Citing Articles

Diarrheal disease and associated factors among children aged 6 to 59 months in Oda Bultum District, Eastern Ethiopia: a community-based cross-sectional study.

Getachew Z, Asefa N, Gashaw T, Birhanu A, Debella A, Balis B BMC Infect Dis. 2024; 24(1):303.

PMID: 38475696 PMC: 10929219. DOI: 10.1186/s12879-024-09169-4.

Association between socioeconomic deprivation and incidence of infectious intestinal disease by pathogen and linked transmission route: An ecological analysis in the UK.

Buczkowska M, Butt S, Jenkins C, Hungerford D, Hawker J, Verlander N Epidemiol Infect. 2023; 151:e109.

PMID: 37313601 PMC: 10369425. DOI: 10.1017/S0950268823000869.

Safety and Immunogenicity of a Bivalent Conjugate Vaccine (ZF0901) in 3-Month- to 5-Year-Old Children in China.

Mo Y, Fang W, Li H, Chen J, Hu X, Wang B Vaccines (Basel). 2022; 10(1).

PMID: 35062694 PMC: 8780113. DOI: 10.3390/vaccines10010033.

Protective multi-epitope candidate vaccine for urinary tract infection.

Oloomi M, Javadi M, Asadi Karam M, Khezerloo J, Haghri Z, Bouzari S Biotechnol Rep (Amst). 2020; 28:e00564.

PMID: 33304840 PMC: 7711219. DOI: 10.1016/j.btre.2020.e00564.

Clinical features, risk factors, and impact of antibiotic treatment of diarrhea caused by in children less than 5 years in Manhiça District, rural Mozambique.

Vubil D, Acacio S, Quinto L, Balleste-Delpierre C, Nhampossa T, Kotloff K Infect Drug Resist. 2018; 11:2095-2106.

PMID: 30464552 PMC: 6219103. DOI: 10.2147/IDR.S177579.

References

Neutra M, Kozlowski P . Mucosal vaccines: the promise and the challenge. Nat Rev Immunol. 2006; 6(2):148-58. DOI: 10.1038/nri1777. View

Huckriede A, Bungener L, Stegmann T, Daemen T, Medema J, Palache A . The virosome concept for influenza vaccines. Vaccine. 2005; 23 Suppl 1:S26-38. DOI: 10.1016/j.vaccine.2005.04.026. View

Fries L, Montemarano A, Mallett C, Taylor D, Hale T, Lowell G . Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults. Infect Immun. 2001; 69(7):4545-53. PMC: 98531. DOI: 10.1128/IAI.69.7.4545-4553.2001. View

Kotloff K, Noriega F, Samandari T, Sztein M, Losonsky G, Nataro J . Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans. Infect Immun. 2000; 68(3):1034-9. PMC: 97245. DOI: 10.1128/IAI.68.3.1034-1039.2000. View

Tokuhara D, Alvarez B, Mejima M, Hiroiwa T, Takahashi Y, Kurokawa S . Rice-based oral antibody fragment prophylaxis and therapy against rotavirus infection. J Clin Invest. 2013; 123(9):3829-38. PMC: 3754275. DOI: 10.1172/JCI70266. View

Manque P, Tenjo F, Woehlbier U, Lara A, Serrano M, Xu P . Identification and immunological characterization of three potential vaccinogens against Cryptosporidium species. Clin Vaccine Immunol. 2011; 18(11):1796-802. PMC: 3209039. DOI: 10.1128/CVI.05197-11. View

Guven E, Duus K, Laursen I, Hojrup P, Houen G . Aluminum hydroxide adjuvant differentially activates the three complement pathways with major involvement of the alternative pathway. PLoS One. 2013; 8(9):e74445. PMC: 3767739. DOI: 10.1371/journal.pone.0074445. View

Orr N, Katz D, Atsmon J, Radu P, Yavzori M, Halperin T . Community-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteers. Infect Immun. 2005; 73(12):8027-32. PMC: 1307051. DOI: 10.1128/IAI.73.12.8027-8032.2005. View

Das B, Gentsch J, Hoshino Y, Ishida S, Nakagomi O, Bhan M . Characterization of the G serotype and genogroup of New Delhi newborn rotavirus strain 116E. Virology. 1993; 197(1):99-107. DOI: 10.1006/viro.1993.1570. View

10.

Lee P, Chen P, Huang Y, Lee C, Lu C, Chang M . Recommendations for rotavirus vaccine. Pediatr Neonatol. 2013; 54(6):355-9. DOI: 10.1016/j.pedneo.2013.03.019. View

11.

Staats H, Montgomery S, Palker T . Intranasal immunization is superior to vaginal, gastric, or rectal immunization for the induction of systemic and mucosal anti-HIV antibody responses. AIDS Res Hum Retroviruses. 1997; 13(11):945-52. DOI: 10.1089/aid.1997.13.945. View

12.

Henriques-Normark B, Tuomanen E . The pneumococcus: epidemiology, microbiology, and pathogenesis. Cold Spring Harb Perspect Med. 2013; 3(7). PMC: 3685878. DOI: 10.1101/cshperspect.a010215. View

13.

Ledon T, Ferran B, Perez C, Suzarte E, Vichi J, Marrero K . TLP01, an mshA mutant of Vibrio cholerae O139 as vaccine candidate against cholera. Microbes Infect. 2012; 14(11):968-78. DOI: 10.1016/j.micinf.2012.04.004. View

14.

Ravichandran M, Ali S, Rashid N, Kurunathan S, Yean Yean C, Ting L . Construction and evaluation of a O139 Vibrio cholerae vaccine candidate based on a hemA gene mutation. Vaccine. 2005; 24(18):3750-61. DOI: 10.1016/j.vaccine.2005.07.016. View

15.

Turner A, Stephens J, Beavis J, Greenwood J, Gewert C, Randall R . Generation and characterization of a live attenuated enterotoxigenic Escherichia coli combination vaccine expressing six colonization factors and heat-labile toxin subunit B. Clin Vaccine Immunol. 2011; 18(12):2128-35. PMC: 3232708. DOI: 10.1128/CVI.05345-11. View

16.

Periaswamy B, Maier L, Vishwakarma V, Slack E, Kremer M, Andrews-Polymenis H . Live attenuated S. Typhimurium vaccine with improved safety in immuno-compromised mice. PLoS One. 2012; 7(9):e45433. PMC: 3454430. DOI: 10.1371/journal.pone.0045433. View

17.

von Seidlein L, Jiddawi M, Grais R, Luquero F, Lucas M, Deen J . The value of and challenges for cholera vaccines in Africa. J Infect Dis. 2013; 208 Suppl 1:S8-14. DOI: 10.1093/infdis/jit194. View

18.

Robbins J, Chu C, Schneerson R . Hypothesis for vaccine development: protective immunity to enteric diseases caused by nontyphoidal salmonellae and shigellae may be conferred by serum IgG antibodies to the O-specific polysaccharide of their lipopolysaccharides. Clin Infect Dis. 1992; 15(2):346-61. DOI: 10.1093/clinids/15.2.346. View

19.

Salvador A, Igartua M, Hernandez R, Pedraz J . An overview on the field of micro- and nanotechnologies for synthetic Peptide-based vaccines. J Drug Deliv. 2011; 2011:181646. PMC: 3134826. DOI: 10.1155/2011/181646. View

20.

Donald R, Flint M, Kalyan N, Johnson E, Witko S, Kotash C . A novel approach to generate a recombinant toxoid vaccine against Clostridium difficile. Microbiology (Reading). 2013; 159(Pt 7):1254-1266. PMC: 3749728. DOI: 10.1099/mic.0.066712-0. View